Home > Insider Trading > Filing (0001214659-18-001759)

Filing Details

Accession Number:: 0001214659-18-001759
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-03-02 18:08:18
Reporting Period:: 2018-03-01

Accepted Time:: 2018-03-02 18:08:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576263	Mirati Therapeutics Inc.	MRTX	Pharmaceutical Preparations (2834)	462693615

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1579771	A Jamie Donadio	C/O Mirati Therapeutics, Inc. 9393 Towne Centre Drive, Ste 200 San Diego CA 92121	Sr. Vp, Cfo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-03-01	9,375	$5.50	9,375	No	4	M	Direct
Common Stock	Acquisiton	2018-03-01	12,500	$5.40	21,875	No	4	M	Direct
Common Stock	Acquisiton	2018-03-01	30,000	$7.30	51,875	No	4	M	Direct
Common Stock	Disposition	2018-03-01	25,600	$26.78	26,275	No	4	S	Direct
Common Stock	Disposition	2018-03-01	25,775	$27.45	500	No	4	S	Direct
Common Stock	Disposition	2018-03-01	500	$28.08	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-03-01	9,375	$0.00	9,375	$5.50
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-03-01	12,500	$0.00	12,500	$5.40
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-03-01	30,000	$0.00	30,000	$7.30

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
20,625	2026-10-26	No	4	M	Direct
37,500	2027-01-25	No	4	M	Direct
0	2020-03-19	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017.
1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (March 20, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.
This transaction was executed in multiple trades at prices ranging from $26.05 to $27.025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $27.05 to $28.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $28.05 to $28.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.